Jefferies analyst Maury Raycroft believes Sage Therapeutics' (SAGE) FDA approval to accelerate a development path for '217 in major depressive disorder and postpartum depression provides a positive read-through for Xenon Pharmaceuticals (XENE). Xenon has two epilepsy programs and one program for hemiplegic migraine, which all have potential in rare disease indications with broader applicability, Raycroft tells investors in a research note. He believes "recent derisking" provides a "great entry point" into Xenon Pharmaceuticals at current share levels. The analyst has a Buy rating on the shares with a $9 price target.